Text size :

Drugs, Prix Galien Italia to Servier for oral targeted therapy against gliomas

ADNKRONOS

November 4, 2026

Rome, Nov 4. (Adnkronos Health) – “The Servier Group in Italy is proud to announce that, on the occasion of the Prix Galien Italia 2026 ceremony, vorasidenib was awarded in the ‘Neuroscience and Psychopharmacology’ category as the first and only oral targeted therapy indicated as monotherapy for the treatment of grade 2 predominantly non-enhancing astrocytoma or oligodendroglioma with Idh1 R132 or Idh2 R172 mutation in adult and adolescent patients aged 12 years or older and weighing 40 kg or more who have undergone surgery only and do not immediately require radiotherapy or chemotherapy.” The company stated this in a note. Vorasidenib – it reads – acts by selectively inhibiting mutated Idh1 and Idh2 enzymes, reducing the abnormal production of 2-Hg (responsible for the pathogenesis of gliomas) and restoring normal cellular differentiation. To date, vorasidenib obtained reimbursement approval in Italy from the Board of Directors of the Italian Medicines Agency (Aifa) on October 15 and is awaiting the publication of the relevant act in the Official Gazette.

According to the jury’s evaluation, chaired by Pier Luigi Canonico, “vorasidenib represents a substantial advance in precision neuro-oncology: it is the first and only targeted therapy for low-grade gliomas with Idh gene mutation, rare brain tumors that often affect young adults, abruptly interrupting life paths, study, work, and future plans. Thanks to a targeted approach, vorasidenib offers the possibility to modify the course of the disease, delay its progression, and postpone the use of more invasive treatments, contributing to preserving cognitive functions and quality of life. A result of great value, because it means offering many young patients more time to continue living, planning, and looking to the future with greater confidence.” “The Prix Galien Italia has always represented a recognition of the excellence of pharmacological research and its ability to transform scientific progress into concrete opportunities for patients – declares Canonico – This year too, the jury wanted to reward therapeutic innovations capable of responding to unmet clinical needs and opening new treatment perspectives in areas with high medical and social impact.”

In Italy, approximately 6,126 new diagnoses of central nervous system tumors were estimated in 2024. Among these, low-grade gliomas with Idh mutation represent a rare form (5-10%) that predominantly affects young adults between 20 and 40 years old. Characterized by a slow but progressive and often unfavorable evolution, these tumors can accompany patients for many years, with a strong impact on quality of life, neurological and cognitive functions, and social and professional spheres. “The arrival of vorasidenib represents a paradigm shift in neuro-oncology, because for the first time we have a molecularly targeted therapy capable of acting directly on the biological mechanisms underlying the disease,” comments Matteo Simonelli, head of Neuro-Oncology Irccs Humanitas Clinical Institute and associate professor of Medical Oncology at Humanitas University. “For over twenty years – he recalls – after surgery, patients diagnosed with grade 2 glioma with Idh1 or 2 gene mutation were generally discussed in a multidisciplinary setting and candidates for an active observation approach, the so-called ‘wait and see’, or for radiotherapy and chemotherapy treatment in the presence of clinical, radiological, and molecular factors suggesting a higher risk of disease progression. Today, however, we have the possibility to intervene early with a treatment that specifically acts on the mutated Idh1 and 2 enzymes, responsible for the production of an oncometabolite, which promotes tumor development and progression.”

Jiji Press

Related

Page TOP